Andexanet alfa: Phase III data

Top-line data from 41 healthy volunteers ages 50-75 in part 1 of the 2-part, double-blind, U.S. Phase III ANNEXA-R trial showed that an 800 mg IV bolus of andexanet alfa met the primary endpoint of re...